A molecular marker for head and neck squamous cell carcinoma and its application

By using SMG6 protein as a molecular marker for head and neck squamous cell carcinoma, the problem of prognostic diagnosis lag in the prior art is solved, more accurate prognostic prediction and tumor suppression effects are achieved, and the quality of life of patients is improved.

CN118671343BActive Publication Date: 2025-04-29南昌大学第一附属医院
0 Cites 0 Cited by

Patent Information

Application Number
CN202410824570.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2025-04-29
Estimated Expiration
2044-06-25

AI Technical Summary

Technical Problem

In the prior art, there is a certain lag in the prognosis method of diagnosing head and neck squamous cell carcinoma, and it is difficult to accurately predict the prognosis of patients.

Method used

SMG6 protein is used as a molecular marker for head and neck squamous cell carcinoma. By analyzing the expression level of SMG6 protein, it assists in diagnosing and predicting patient prognosis, and develops targeted therapeutic drugs to inhibit tumor growth.

Benefits of technology

The expression analysis of SMG6 protein can more accurately predict the prognosis of HNSCC patients, provide more effective auxiliary diagnostic tools, and inhibit tumor growth through targeted therapeutic drugs to improve patients' quality of life.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention discloses a molecular marker for head and neck squamous cell carcinoma and its application. The molecular marker contains SMG6 protein. The present invention also provides the application of the molecular marker for head and neck squamous cell carcinoma in auxiliary diagnosis products, prognosis prediction models, as a target in screening anti-head and neck squamous cell carcinoma drugs, and as a head and neck squamous cell carcinoma tumor inhibitor. The present invention has developed a group of molecular markers for predictive prognosis diagnosis of HNSCC. The present invention analyzes the prognostic significance of SMG6 protein in HNSCC and finds that increased expression of SMG6 protein is positively correlated with a good prognosis of HNSCC patients. The present invention confirms through in vivo and in vitro experiments that SMG6 protein plays a role in inhibiting tumors in HNSCC.
Need to check novelty before this filing date? Find Prior Art